UCLA Health Jonsson Comprehensive Cancer Center | Strategic Alliance Partners

Latest from UCLA Health Jonsson Comprehensive Cancer Center


Dr. Singh on Drug Development for Patients With Soft Tissue Sarcomas

May 31, 2018

Arun S. Singh, MD, associate professor, Department of Medicine, Division of Hematology/Oncology, University of California, Los Angeles, discusses drug development for the treatment of patients with soft tissue sarcomas.

Dr. Krakow on Genetic Testing in Ovarian Cancer

May 30, 2018

Deborah Krakow, MD, professor and chair, Department of Obstetrics and Gynecology, professor of Orthopaedic Surgery and Human Genetics, University of California, Los Angeles, discusses genetic testing in patients with ovarian cancer.

Dr. Memarzadeh on p53 Reactivation in Ovarian Cancer

May 29, 2018

Sanaz Memarzadeh, MD, PhD, gynecologic oncologist, professor of obstetrics and gynecology, University of California, Los Angeles, discusses p53 reactivation in the treatment of patients with ovarian cancer.

Dr. Slamon on PARP Inhibitors in Ovarian Cancer

May 25, 2018

Dennis J. Slamon, MD, PhD, director, Clinical/Translational Research, Revlon/University of California, Los Angeles (UCLA) Women's Cancer Research Program, Jonsson Comprehensive Cancer Center, UCLA, discusses the use of PARP inhibitors in the treatment of patients with ovarian cancer.

Dr. Hurvitz on the FDA Approval Process for Biosimilars

April 30, 2018

Sara Hurvitz, MD, director of the Breast Oncology Program, medical director of the Clinical Research Unit, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses when to use a biosimilar over the originator drug.

Dr. McCloskey on Postoperative Radiation in Patients With Breast Cancer

April 27, 2018

Susan A. McCloskey, MD, MSHS, assistant professor of radiation oncology, University of California Los Angeles (UCLA) Medical Center, Jonsson Comprehensive Cancer Center, discusses the evolution of postoperative radiation in patients with breast cancer.

Dr. Slamon on the Use of Trastuzumab and Bevacizumab Biosimilars in Breast Cancer

April 25, 2018

Dennis J. Slamon, MD, PhD, director, Clinical/Translational Research, Revlon/University of California, Los Angeles (UCLA) Women's Cancer Research Program, Jonsson Comprehensive Cancer Center, UCLA, discusses the use of biosimilars in clinical practice.

Dr. Callahan on Endocrine Therapy in Patients With ER-Positive Breast Cancer

April 24, 2018

Rena D. Callahan, MD, assistant clinical professor of medicine, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses the use of endocrine therapy in patients with estrogen receptor (ER)-positive breast cancer.

Dr. Aberle on Novel Approaches to Screening for Lung Cancer

September 30, 2016

Denise R. Aberle, MD, professor of Radiology in the School of Medicine, of Bioengineering in the Henry Samueli School of Engineering and Applied Science, UCLA Medical Center, discusses novel approaches to screen patients for lung cancer.

Dr. Sanaz Memarzadeh on Chemotherapy Resistant Tumor Cells in Ovarian Cancer

December 16, 2015

Sanaz Memarzadeh, MD, PhD, associate professor of Obstetrics and Gynecology, and the director of the Gynecologic Oncology Discovery Lab at UCLA, discusses her preclinical research on resistant tumor cells in ovarian cancer.

x